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period. METHODS: The 5% Medicare national sample Parts A, B, & D (n=1,229,698) 
was used to estimate ordinary least squares regression models for prospective 
community payment to predict year-2 (2008) annualized medical (CMS-HCC) and 
pharmacy (CMS-RxHCC) expenditures from year-1 (2007) demographics, CMS 
model inputs, and the MEM. Gamma-distributed, log-linked generalized linear 
models were estimated for zero-inflated medical expenditure outcomes. OLS 
models were also estimated using truncated and log-transformed expenditures. 
RESULTS: The CMS-HCC model (OLS R2=0.0698) was only marginally improved 
by the addition of MEM (R2=0.0706). The CMS-RxHCC model (R2=0.1485; Grouped 
R2=0.3696) was markedly improved by the addition of MEM (R2=0.2489; Grouped 
R2=0.7692). Further, the predictive ratios for pharmacy expenditure deciles show 
that the CMS-RxHCC+MEM model more accurately predicts in 8 out of 10 deciles 
compared to the CMS-RxHCC alone. CONCLUSIONS: Although adding MEM to 
the CMS-HCC models used to predict medical expenditures does not appear to be 
a useful method of enhancing risk-adjusted payments, the MEM performed 
particularly well with the CMS-RxHCC model, predicting year-2 pharmacy 
expenditures. Pharmacy expenditures are generally less variable compared to 
medical expenditures, making improvements to prediction more difficult for 
medical models. Incorporating the MEM into Medicare Part D risk-adjustment 
models (CMS-RxHCC) would improve risk-adjusted capitated payments from 
both the perspectives of CMS and the health plans and mitigate adverse risk 
selection.  
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WHETHER THE TREATMENT EXPENDITURES OR THE PHARMACEUTICAL 
EXPENDITURES OF SOCIAL SECURITY INSTITUTION (SSI) HAVE A HIGHER 
INCREASE RATE BETWEEN 2005 AND 2011 IN TURKEY?  
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OBJECTIVES: Turkey has accomplished remarkable improvements in terms of 
health status particularly after the implementation of the Health Transformation 
Program (HTP). Within the scope of HTP, the number of people covered by public 
health insurance, the number of hospital visits and also the number of physician 
consultation per capita has increased and disparities of benefit package between 
different sick funds have been unified. As a result, total health care expenditures 
have increased at a large extent. The aim of this study is to evaluate the rates of 
increases in the expenditures of Social Security Institution (SSI) in terms of 
pharmaceutical and treatment expenditures between 2005 and 2011. METHODS: 
Databases of SSI, IMS, Ministry of Health and AIFD have been searched for the 
period of 2005 to 2011. Rates of increase in the health expenditures, number of 
people covered by public health insurance, hospital visits and the number of 
physician consultation per capita have been evaluated and compared. RESULTS: 
Between 2005 and 2011, coverage of public health insurance has risen from 89 to 
96, physician consultation per capita has increased 63.8%, total health 
expenditures of SSI have increased 18% with a 23% increase in treatment 
expenditures and 12% increase in pharmaceutical expenditures. CONCLUSIONS: 
As a result of increase in the coverage of public health insurance and the number 
of hospital visits, treatment expenditures have risen at a large extent. But on the 
other hand, pharmaceutical expenditures’ increase rate was not at the same 
level. The main reasons are the global budget policy and the increases at the 
mandatory institutional discounts, which are being used as a major cost 
containment tool. Despite the success in the containment of pharmaceutical 
expenditures, any major cost containment policy for treatment expenditures 
haven’t been implicated, and in addition treatment expenditures are continuing 
to rise.  
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SURFING THE GERMAN BENEFIT ASSESSMENT WAVE  
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OBJECTIVES: The German Pharmaceutical Market Restructuring Act (AMNOG) 
was implemented January 2011 and heralded as one of the most important 
European health care reforms to impact the pharmaceutical industry. Two years 
into its implementation the industry is still adapting and learning to navigate the 
new process effectively. This research assessed the impact of the AMNOG reform 
since January 2011 to inform new product development and launch strategies. 
METHODS: To identify the criteria for successful benefit assessment outcomes 
and their relative importance in justifying price premiums, the benefit 
assessment dossiers submitted to-date were analysed in a systematic approach. 
Findings were then validated through in-depth interviews with national level 
stakeholders. RESULTS: As of January 2013, 29 products have been launched in 
Germany since the AMNOG reform: five achieved a considerable additional 
benefit, ten received a minor additional benefit and three received an 
unquantifiable additional benefit. However, almost half of the products 
submitted for benefit assessment were not granted any additional benefit, 
indicating that two years after the implementation of the AMNOG reform, 
manufacturers are still adapting to the changing payer environment. Reasons for 
unsuccessful benefit assessment outcomes point to the importance of building a 
dialogue with the G-BA before dossier submission and understanding the G-BA’s 
criteria for comparator selection. They also highlight the importance of opting 
for a clinical trial design, acceptable within IQWiG’s benefit assessment 
methodology, amenable to robust comparative studies with the chosen 
comparator and long-term data collection. CONCLUSIONS: The new German 
HTA process is still an evolving process and it is important to learn from the 
completed benefit assessments and price negotiations. This understanding will 
help secure successful outcomes for products currently in development and 
patient access to novel therapies, not only in Germany, but in other countries, 
which continue to look at the German HTA model for reference.  
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OBJECTIVES: Relational continuity of care (COC) refers to the quality and 
duration of the relationship between a patient and provider. We aimed to 
determine whether increased COC is associated with decreased health care 
utilization in patients with chronic conditions. METHODS: We searched 
MEDLINE, EMBASE, CINAHL and the Cochrane Library from 2002 to December 
2011 to identify studies comparing outcomes in patients with high, medium, and 
low COC. Chronic disease cohorts were constructed using administrative 
databases from Ontario, Canada. Resource use and costs for each condition were 
calculated over five years and utility values were identified in the literature; 
estimates of clinical effect were applied to each cohort. The expected cost (2012 
Canadian dollars) and QALY gain of improving continuity was explored in a 
sensitivity analysis. RESULTS: Thirteen observational studies were included in 
the systematic review. All assessed continuity using administrative data to 
measure visits to primary care providers. Results were not pooled due to 
variability in COC indices and patient populations. However, across all cohorts 
people with high COC had significantly fewer hospitalizations and emergency 
department visits compared to people with low and medium continuity. As a 
result, people with high continuity incur fewer health care costs compared to 
those with lower continuity . It is likely that interventions designed to improve 
COC would represent value for money, even if only marginally effective. 
CONCLUSIONS: These initiatives could take the form of policy decisions 
governing the financing and delivery of health care in the community. Such 
changes may have far-reaching consequences for patients and providers 
throughout the system; more research in this area is needed. The literature was 
limited by an absence of evidence in family health teams and among providers 
who are not physicians.  
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OBJECTIVES: This study identifies factors that influence physicians’ use of 
medical resources. METHODS: We used the Healthcare Cost and Utilization 
Project (HCUP) State Inpatient Databases (SID), the American Hospital 
Association Annual Survey Database, and the Area Resource File in this analysis. 
Our hospital data for 2008 were drawn from Arizona and Florida, and physician 
information was obtained from medical boards of each state where we used 
physicians’ license numbers to register each hospital inpatient visit to a 
physician. Over 2.5 million inpatient records were used in the analysis. We 
employed linear cost models using all hospital inpatient stays registered to 
physicians for whom we had information on observable characteristics. We also 
estimated multilevel regression models that clustered hospital inpatient visits 
across physicians. We then repeated our linear regression analysis focusing 
separately on physicians working only in either teaching or non-teaching 
hospitals to address possible endogeneity of patient case mix and unobservable 
physician-specific factors that may not be completely addressed via regression 
models. Finally, we re-estimated our multilevel model using all hospital 
inpatient stays registered to two subsamples of physicians based on their 
observable characteristics by employing propensity score nearest-neighbor (NN) 
matching without replacement. RESULTS: Our key findings remained the same 
across all estimations: 1) the costs of hospital inpatient stays registered to female 
physicians or foreign-trained physicians are significantly lower than the costs of 
hospital stays registered to male physicians or U.S.-trained physicians; 2) the 
costs of hospital stays registered to physicians with more experience is lower 
when compared to physicians with less experience; and 3) there is substantial 
variation in costs of hospital inpatient stays across board certified physician 
specialties, where surgeons and cardiologists are generally associated with 
higher costs of hospital inpatient stays. CONCLUSIONS: Our findings 
demonstrate that physicians’ characteristics have a significant impact on the 
costs of hospital inpatient stays.  
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OBJECTIVES: This study empirically investigates “medical litigations” against 
physicians to assess its impact on hospital inpatient costs registered to 
physicians facing medical litigations and the spillover effects on other physician 
colleagues. METHODS: We employ generalized linear models to estimate the 
impact of the medical litigation against an individual physician on hospital 
inpatient costs. We also estimate the spillover effects of the medical litigation 
against an individual physician on the costs of hospital inpatient stays registered 
to other physicians with no medical litigation history practicing within the same 
hospitals for each of the following board certified physician specialty groups: 
Cardiologists, general practitioners, neurologists, obstetricians and/or 
gynecologists, pediatricians, psychologists, surgeons, and urologists. We use the 
Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID), 
the American Hospital Association Annual Survey Database, and the Area 
Resource File in this analysis. Our hospital data for 2008 are drawn from Florida, 
and physician information was obtained from the state’s medical board where 
we use physicians’ license numbers to register each hospital inpatient visit to a 
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physician. Over 1.7 million inpatient records are used in the analysis. RESULTS: 
Our risk-adjusted results show that medical litigation against physicians 
increase the average cost of inpatient hospital visits about 11%. We find that 
hospital inpatient costs registered to surgeons with no medical litigation history 
is higher (about 28%) at hospitals where there is at least one surgeon facing 
medical litigations when compared to the hospitals where there is no surgeon 
associated with medical litigation history. The magnitude of spillover effects are 
in between 2 percent and 28% for other physician specialties except for 
obstetricians and/or gynecologists for whom we found no spillover effects. 
CONCLUSIONS: Medical litigation against physicians increases the hospital 
inpatient costs. There is significant variation in spillover effects of medical 
litigations across major board certified physician groups.  
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OBJECTIVES: The influence of financial status on life satisfaction is well 
discussed among economists. In contrast, population surveys indicate that 
general health is viewed by most subjects as key contributor to life satisfaction. 
We therefore aimed at analyzing the reciprocal impacts of morbidity and 
economic status on life satisfaction as a health outcome variable. METHODS: In 
2007, two representative adult samples of the Kantar Health European 
Healthcare Panel in Germany and UK were surveyed (n=72.605) and self-reports 
on 22 chronic diseases (12-month-prevalences summed up to a multimorbidity 
score) and household income (net household income in GBP) were collected. In 
2012, a subsample of 4.008 individuals was re-contacted and participants 
completed a health status and a validated life satisfaction questionnaire (IZA 
LSQ) with five domains: Life as a whole, work, social contacts, income and health 
(Kapteyn et al. 2008). The five-year impact of multimorbidity and income on life 
satisfaction was estimated using a stepwise multiple linear regression model, 
considering age and gender as confounders. RESULTS: Multimorbidity and 
income were moderately but significantly correlated with general life 
satisfaction (linear regression beta-coefficients: beta=0.26 resp. 0.25; p<0.01). 
Correlations with the outcome categories satisfaction with work, social contacts, 
income and health were also positive (beta coefficients between 0.15 and 0.40; all 
p<0.01). All effects were independent of age and gender. As expected, disease 
status had the greatest influence on satisfaction with health (beta=0.40) but also 
on satisfaction with work and functional capacity (beta=0.25). CONCLUSIONS: 
The results demonstrate specific, independent but complementary impacts of 
health status and income on life satisfaction and its domains. The impact on 
societal resource allocation decisions is being discussed: Optimal population 
based life satisfaction might require combining health care and economic 
improvements.  
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OBJECTIVES: One of the key drivers behind the UK’s health service reforms has 
been to reduce regional and local variability of access to care and medicines. 
However, the devolved countries in the UK also have individual challenges- 
recently the Scottish Health Secretary, Alex Neil, said a review of the Scottish 
Medicines Consortium (SMC) was launched in response to “concerns about 
variable access to medicines” raised by some clinicians, charities and patients. 
This study interviewed NHS leaders in Scotland to understand the reasons 
behind this variable uptake of SMC guidance. METHODS: Secondary research to 
understand NHS drivers & local decision-making processes followed by 
1:1stakeholder interviews with 12 NHS Senior payers across Scotland. RESULTS: 
Scotland’s NHS is renowned as being at the forefront of new technologies and 
innovation. Uptake of guidance, like that of NICE is mandated, however, Health 
Boards (HBs) are facing many challenges to balance the national quality agenda 
with a need to make tough efficiency savings to ensure HBs continue to deliver 
for the local population. Whilst national groups such as NICE and SMC are seen 
as leaders within the HTA space, it would appear that a huge challenge within 
countries adopting these HTA recommendations and guidance will continue to 
be equitable implementation across the country, however this will now be 
greatly influenced by local decisions on affordability, similar to the decentralized 
picture in Italy and Spain. CONCLUSIONS: The implementation of SMC guidance 
was seen as a national driver by Scottish Health Boards (HBs). Implementation 
decisions are taken at a HB level and a key driver influencing implementation is 
now local affordability and infrastructure capacity, of interest for many payers is 
the challenge of medicines optimization  
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OBJECTIVES: To evaluate the consistency of information given in drug brochures 
by pharmaceutical companies METHODS: Total of 500 drug brochures were 
collected from the doctors’ clinics in Pakistan and 473 brochures were collected 
from the general practitioners’ clinics in Malaysia. After comprehensive scrutiny, 
a total of 498 brochures were included and evaluated for the study. An 
evaluation form was developed based on the criteria given by WHO, FIPMA, 
DCOMOH(Pakistan) and PhAMA. The data was analyzed using SPSS. To 
summarize the data, descriptive statistics (frequencies, percentages,) were 
calculated and Chi-square test and Fisher’s exact test were applied as inferential 
statistics. A Pvalue of less than 0.05 was considered as statistical significance for 
all the tests. RESULTS: The Cronbach’s coefficient Alpha value was 0.729 (n=50). 
The study found that the dosage form was presented significantly (P=0.009) less 
in national companies’ (NCs) brochures as compared to MNCs. MNCs were found 
significantly adherent to the standard criteria for brochures as compared to NCs 
for presenting drug interactions (P<0.001), precautions (P<0.001) and expected 
ADRs (P<0.001). National companies were found significantly (P<0.001) adherent 
to the standard criteria in terms of presenting contraindications and warnings. 
MNCs were significantly better (P=0.009) in terms of including contact 
information in the brochures. A significantly higher number of Malaysian 
brochures providing information about drug interactions (P<0.001), precautions 
(P<.001), expected ADRs (P<0.001) and contraindications (P<0.001). On average 3 
(median, IQR=5) references were used in the brochures out of which on average 2 
(median, IQR=6) references were understandable. The references having enough 
information to access particular study were considered understandable. 
CONCLUSIONS: The drug information given in the brochures, discrepancies are 
observed mainly in drug safety related information like side effects, possible 
ADRs, precautions etc. The references cited in the brochures were also found to 
be inappropriate and incomplete.  
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OBJECTIVES: Death after complication, or “Failure to Rescue” (FTR), contributes 
to differences in risk-adjusted mortality rates among trauma centers and is 
considered an indicator of quality of care. The objective of our study was to 
assess the effect of specific comorbidities on FTR outcomes in trauma patients. 
METHODS: We performed a retrospective cohort study that analyzed patient 
records included in the National Trauma Data Bank (NTDB) from years 2008-
2010. The dataset was limited to patients with an injury severity score greater 
than 9 and who were between the ages of 18 and 64. Only patients treated at 
hospitals with adequate complication reporting were included in the analysis. 
Cox regression modeling was used to determine the contribution of individual 
comorbidities to FTR outcomes while controlling for injury severity, head  
injury, mechanism of injury, hypotension, age, gender, race, and insurance  
type. RESULTS: Diabetes, congestive heart failure, history of myocardial 
infarction, and dialysis were associated with greater hazard ratios for FTR [HR 
1.18 (CL 1.05, 1.32), 1.45 (1.16, 1.81), 1.30 (1.01, 1.67), 2.02 (1.50, 2.72), respectively]. 
Obesity and hypertension were not with associated with increased risk of  
FTR. CONCLUSIONS: Pre-existing comorbidities contributed significantly to  
risk of death after complication in the trauma population. Identifying  
processes of care that lead to better management of complications in  
patients with comorbidities would improve trauma centers' overall mortality 
outcomes.  
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OBJECTIVES: This study aims to explore safety culture dimensions among health 
care professionals using AHRQ (Agency for Healthcare Research and Quality)’s 
survey questionnaire(Hospital Survey of patient Safety Culture: HSOPSC). 
METHODS: We surveyed nationwide the situation of patient safety culture in 13 
hospitals allowed for additional costs on patient safety measures under the 
social insurance medical fee schedule. The questionnaire consists of seven unit-
level aspects of safety culture including 24 items, three hospital-level including 
11 items, and four outcome variables including nine items. RESULTS: An average 
number of beds was 360 beds (63 to 1,354 beds). With regard to ownership, 13 
hospitals included three municipality and local incorporated agency hospitals, 
one public hospital, two juridical person with social insurance hospitals, six 
medical corporation hospitals, and one other hospital. Number of all 
respondents was 5,118 persons (response rate: 88.9%), and included 295 
physicians (90.8%), 2,909 nurses (95.5%), and 146 pharmacists (96.7%). In terms of 
12 dimensions, the overall average positive response rate (RR) for the 12 patient 
safety dimensions of the HSOPS was 49.2%, extremely lower than the average 
positive RR for the AHRQ data (61%). In terms of health care professionals, the 
overall average positive RR for pharmacists (46.2%) was lower than that for 
physicians and nurses (49.6% and 49.4%). With regard to pharmacists, the 
average positive RRs for eight dimensions of the 12 dimensions were the lowest 
among three professionals, and three average positive RRs were the highest; 
Frequency of event reporting (pharmacists: physicians: 
nurses=73.6%:53.3%:67.9%), Non-punitive response to error (48.8%:42.6%:40.4%), 
and Staffing (29.1%:27.0%:25.4%). CONCLUSIONS: The HSOPSC measurement 
provides the evidence for assessment of patient safety culture in Japan’s 
hospitals. This result that patient safety culture has been in a state of 
development, compared with the US hospitals. And, pharmacists have to take a 
considerable interest patient safety in Japan.  
